Development of the Manchester Cancer Research Centre Molecular Tumour Board for matching patients to clinical trials based on tumour and ctDNA genetic profiling

Background: Advances in Next Generation Sequencing (NGS) are enabling detailed molecular analysis of tumour and circulating tumour DNA (ctDNA). Combined with the expanding development of targeted therapies we are in the era of Precision Medicine. Molecular Tumour Boards (MTB) are needed to interpret genomic data and inform on clinically relevant matched therapies. We describe our experience of setting up a MTB to deliver a world-class genomic...